199 related articles for article (PubMed ID: 29517035)
1. A CRISPR edit for heart disease.
King A
Nature; 2018 Mar; 555(7695):S23-S25. PubMed ID: 29517035
[No Abstract] [Full Text] [Related]
2. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
3. Gene-Editing Technology Accelerates Cardiovascular Research: Clinical Applications Being Explored.
Kuehn BM
Circulation; 2018 Feb; 137(9):973-974. PubMed ID: 29483173
[No Abstract] [Full Text] [Related]
4. CRISPR Correction of Duchenne Muscular Dystrophy.
Min YL; Bassel-Duby R; Olson EN
Annu Rev Med; 2019 Jan; 70():239-255. PubMed ID: 30379597
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas correction of muscular dystrophies.
Zhang Y; Nishiyama T; Olson EN; Bassel-Duby R
Exp Cell Res; 2021 Nov; 408(1):112844. PubMed ID: 34571006
[TBL] [Abstract][Full Text] [Related]
6. Gene Editing for the Treatment of Hypercholesterolemia.
Hoekstra M; Van Eck M
Curr Atheroscler Rep; 2024 May; 26(5):139-146. PubMed ID: 38498115
[TBL] [Abstract][Full Text] [Related]
7. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.
Ousterout DG; Kabadi AM; Thakore PI; Majoros WH; Reddy TE; Gersbach CA
Nat Commun; 2015 Feb; 6():6244. PubMed ID: 25692716
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Myoediting Attenuates Cardiac Abnormalities in Human and Mouse Models of Duchenne Muscular Dystrophy.
Atmanli A; Chai AC; Cui M; Wang Z; Nishiyama T; Bassel-Duby R; Olson EN
Circ Res; 2021 Sep; 129(6):602-616. PubMed ID: 34372664
[TBL] [Abstract][Full Text] [Related]
9. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.
Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD
Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224
[TBL] [Abstract][Full Text] [Related]
10. Application of CRISPR-Cas system in gene therapy: Pre-clinical progress in animal model.
Guan L; Han Y; Zhu S; Lin J
DNA Repair (Amst); 2016 Oct; 46():1-8. PubMed ID: 27519625
[TBL] [Abstract][Full Text] [Related]
11. Cautious welcome for gene editing of Duchenne muscular dystrophy in animal model.
Hawkes N
BMJ; 2016 Jan; 351():h7033. PubMed ID: 26729900
[No Abstract] [Full Text] [Related]
12. CRISPR editing as a therapeutic strategy for Duchenne muscular dystrophy-anti-Cas9 immune response casts its shadow over safety and efficacy.
Dowling JJ
Gene Ther; 2022 Nov; 29(10-11):575-577. PubMed ID: 35194186
[No Abstract] [Full Text] [Related]
13. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
Doetschman T; Georgieva T
Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
[TBL] [Abstract][Full Text] [Related]
14. Neuromuscular disease: CRISPR/Cas9 gene-editing platform corrects mutations associated with Duchenne muscular dystrophy.
Wood H
Nat Rev Neurol; 2015 Apr; 11(4):184. PubMed ID: 25752950
[No Abstract] [Full Text] [Related]
15. PCSK9 inhibitor therapy in homozygous familial defective apolipoprotein B-100 due to APOB R3500Q: A case report.
Andersen L; Davis T; Testa H; Andersen RL
J Clin Lipidol; 2017; 11(6):1471-1474. PubMed ID: 28988723
[TBL] [Abstract][Full Text] [Related]
16. Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3.
Chadwick AC; Evitt NH; Lv W; Musunuru K
Circulation; 2018 Feb; 137(9):975-977. PubMed ID: 29483174
[No Abstract] [Full Text] [Related]
17. Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice.
Xu L; Gao Y; Lau YS; Han R
J Vis Exp; 2018 Aug; (138):. PubMed ID: 30124643
[TBL] [Abstract][Full Text] [Related]
18. Neuromuscular disease: Genome editing shows promise in an in vivo model of Duchenne muscular dystrophy.
Wood H
Nat Rev Neurol; 2016 Feb; 12(2):63. PubMed ID: 26782331
[No Abstract] [Full Text] [Related]
19. Gene Editing for Duchenne Muscular Dystrophy Using the CRISPR/Cas9 Technology: The Importance of Fine-tuning the Approach.
Tremblay JP; Iyombe-Engembe JP; Duchêne B; Ouellet DL
Mol Ther; 2016 Nov; 24(11):1888-1889. PubMed ID: 27916992
[No Abstract] [Full Text] [Related]
20. The promise and challenge of therapeutic genome editing.
Doudna JA
Nature; 2020 Feb; 578(7794):229-236. PubMed ID: 32051598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
